538 related articles for article (PubMed ID: 28252092)
1. The drug-resistant bacteria that pose the greatest health threats.
Willyard C
Nature; 2017 Feb; 543(7643):15. PubMed ID: 28252092
[No Abstract] [Full Text] [Related]
2. Drug development: Time for teamwork.
May M
Nature; 2014 May; 509(7498):S4-5. PubMed ID: 24784427
[No Abstract] [Full Text] [Related]
3. A three-step plan for antibiotics.
Nature; 2014 May; 509(7502):533. PubMed ID: 24877183
[No Abstract] [Full Text] [Related]
4. Accelerating resistance, inadequate antibacterial drug pipelines and international responses.
Theuretzbacher U
Int J Antimicrob Agents; 2012 Apr; 39(4):295-9. PubMed ID: 22341298
[TBL] [Abstract][Full Text] [Related]
5. Stimulating antibiotic development.
Tillotson G
Lancet Infect Dis; 2010 Jan; 10(1):2-3. PubMed ID: 20129141
[No Abstract] [Full Text] [Related]
6. Fourteen years in resistance.
Livermore DM
Int J Antimicrob Agents; 2012 Apr; 39(4):283-94. PubMed ID: 22386741
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of the ESKAPE pathogens.
Pendleton JN; Gorman SP; Gilmore BF
Expert Rev Anti Infect Ther; 2013 Mar; 11(3):297-308. PubMed ID: 23458769
[TBL] [Abstract][Full Text] [Related]
8. Development of new antibacterials: a laudable aim, but what is the value?
Tillotson GS
Clin Infect Dis; 2010 Sep; 51(6):752-3; author reply 754-5. PubMed ID: 20731567
[No Abstract] [Full Text] [Related]
9. Novel Programs and Discoveries Aim to Combat Antibiotic Resistance.
Hampton T
JAMA; 2015 Jun 23-30; 313(24):2411-3. PubMed ID: 26039283
[No Abstract] [Full Text] [Related]
10. Questions about the 10 x '20 Initiative.
Outterson K; Powers JH; Gould IM; Kesselheim AS
Clin Infect Dis; 2010 Sep; 51(6):751-2; author reply 754-5. PubMed ID: 20731566
[No Abstract] [Full Text] [Related]
11. Letter in response to the Infectious Diseases Society of America's 10 x '20 Initiative.
Burgess DS; Slain D; Mohr J; Wong-Beringer A; Destache C; Suda K
Clin Infect Dis; 2010 Sep; 51(6):753; author reply 754-5. PubMed ID: 20731568
[No Abstract] [Full Text] [Related]
12. What are the economic barriers of antibiotic R&D and how can we overcome them?
Renwick M; Mossialos E
Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
[No Abstract] [Full Text] [Related]
13. The bacteria fight back.
Taubes G
Science; 2008 Jul; 321(5887):356-61. PubMed ID: 18635788
[No Abstract] [Full Text] [Related]
14. Antibacterial R&D incentives.
Laxminarayan R; Powers JH
Nat Rev Drug Discov; 2011 Sep; 10(10):727-8. PubMed ID: 21959280
[No Abstract] [Full Text] [Related]
15. Antibacterial resistance: is there a way out of the woods?
Marra A
Future Microbiol; 2011 Jul; 6(7):707-9. PubMed ID: 21797683
[No Abstract] [Full Text] [Related]
16. [Development status of new antibacterials].
Yamano Y
Nihon Rinsho; 2012 Feb; 70(2):315-9. PubMed ID: 22413538
[TBL] [Abstract][Full Text] [Related]
17. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.
Spellberg B; Sharma P; Rex JH
Nat Rev Drug Discov; 2012 Feb; 11(2):168. PubMed ID: 22293569
[No Abstract] [Full Text] [Related]
18. New β-lactam antibiotics and β-lactamase inhibitors.
Bush K; Macielag MJ
Expert Opin Ther Pat; 2010 Oct; 20(10):1277-93. PubMed ID: 20839927
[TBL] [Abstract][Full Text] [Related]
19. The drug push.
Servick K
Science; 2015 May; 348(6237):850-3. PubMed ID: 25999488
[No Abstract] [Full Text] [Related]
20. Combatting antimicrobial resistance globally.
Sugden R; Kelly R; Davies S
Nat Microbiol; 2016 Sep; 1(10):16187. PubMed ID: 27670123
[No Abstract] [Full Text] [Related]
[Next] [New Search]
